The FDA recently approved Lipfendra, an oral medication for treating high cholesterol and heterozygous familial hypercholesterolemia. This drug marks the first time a PCSK9 inhibitor has been available as a daily pill. By blocking the PCSK9 protein, the medication prevents the breakdown of liver receptors, which allows the body to clear more LDL cholesterol from the bloodstream. Cardiologists note that the medication effectively lowers bad cholesterol levels, but it is not a direct replacement for existing treatments like statins.
While Lipfendra showed significant results in clinical trials, it has not been tested head-to-head against statins. Statins remain the standard of care due to decades of data regarding their ability to prevent heart attacks and strokes. Lipfendra lacks this long-term cardiovascular outcomes data, meaning its primary role for now is as an add-on therapy for patients who cannot reach their cholesterol goals with statins alone or who struggle with statin tolerance.
Patients should be aware of the specific requirements for taking Lipfendra. It must be taken on an empty stomach with water, black coffee, or plain tea. After swallowing the pill, patients must wait at least 30 minutes before consuming anything else. This strict daily routine may influence whether a patient chooses this option over an injectable PCSK9 inhibitor that requires dosing only once every two weeks.
Lipfendra is intended for adult use and has not been approved for minors. Furthermore, medical guidance suggests stopping the medication if a patient becomes pregnant. Anyone interested in this treatment should discuss their specific risk profile and current cholesterol levels with a healthcare provider to determine if the medication fits their health management plan.